Latest News for: amyotrophic

Edit

Amyotrophic Lateral Sclerosis Clinical Trials Analysis Report, 2025 - Understand Global Trial Trends and Assess ...

Nasdaq Globe Newswire 27 Aug 2025
Dublin, Aug. 27, 2025 (GLOBE NEWSWIRE) -- The "Amyotrophic Lateral Sclerosis - Global Clinical Trials Review, 2025" has been added to ResearchAndMarkets.com's offering ... .
Edit

Coya Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

PR Newswire 25 Aug 2025
This proprietary immunomodulatory biologic combination therapy is being developed for the treatment of patients with amyotrophic lateral sclerosis (ALS).  ... About Amyotrophic Lateral Sclerosis.
Edit

Amyotrophic Lateral Sclerosis Clinical Trials, Companies, Therapies, Pipeline | Ionis Pharmaceuticals, 1ST Biotherapeutics, Scholar Rock, ...

GetNews 22 Aug 2025
"Amyotrophic Lateral Sclerosis Clinical Trials" ... DelveInsight reports that the Amyotrophic Lateral Sclerosis (ALS) pipeline involves over 75 key companies actively developing more than 80 investigational therapies.
Edit

For Some Patients, the ‘Inner Voice’ May Soon Be Audible

New York Times 14 Aug 2025
In a recent study, scientists successfully decoded not only the words people tried to say but the words they merely imagined saying ... .
Edit

Amyotrophic Lateral Sclerosis Market Outlook 2034 – Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight

GetNews 13 Aug 2025
"Amyotrophic Lateral Sclerosis Market". The Amyotrophic Lateral Sclerosis (ALS) market in the 7 major markets (7MM) was valued at approximately USD 1,000 million in 2023. Amyotrophic Lateral Sclerosis Market Summary.
Edit

Amyotrophic Lateral Sclerosis Pipeline Insight 2025: 75+ Companies Accelerating Innovation Across Genetic and Neuroinflammatory Targets ...

GetNews 26 Jul 2025
"Amyotrophic Lateral Sclerosis Pipeline" ... Key Takeaways from the Amyotrophic Lateral Sclerosis Pipeline Report ... BCLI) announced FDA clearance to begin its Phase IIIb trial of NurOwn® for treating amyotrophic lateral sclerosis (ALS).
Edit

Amyotrophic Lateral Sclerosis (ALS) Market Forecast Report 2025-2034 | Advancements in Therapeutics and Approved Medications ...

Nasdaq Globe Newswire 23 Jul 2025
Rising ALS prevalence, demand for treatments, and advancing research propel growth ... Rising ALS prevalence, demand for treatments, and advancing research propel growth ... .
Edit

Amyotrophic Lateral Sclerosis (ALS) Market Analysis Report 2025-2035: Breakthrough Therapeutic Solutions Emerge in ALS Treatment ...

The Galveston Daily News 21 Jul 2025
DUBLIN--(BUSINESS WIRE)--Jul 21, 2025-- ....
Edit

Amyotrophic Lateral Sclerosis (ALS) Market Analysis Report 2025-2035 | Increase in Clinical Trials and Investments ...

Nasdaq Globe Newswire 14 Jul 2025
The ALS market is witnessing robust growth driven by increased disease awareness, advancements in genetic research, and an expanding pipeline of therapeutic drugs ... Key challenges include high treatment costs and limited awareness in emerging markets ... .
Edit

Klotho Neurosciences, Inc. Granted FDA Orphan Drug Designation for KLTO-202 for Treatment of Amyotrophic Lateral Sclerosis (“ALS” or “Lou Gehrig’s Disease”) (Form 8-K) (Klotho Neuroscience Inc)

Public Technologies 10 Jul 2025
). Klotho Neurosciences, Inc. Granted FDA Orphan Drug Designation for KLTO-202 for Treatment of Amyotrophic Lateral Sclerosis ("ALS" or "Lou Gehrig's Disease"). NEW YORK, July 10, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc.
Edit

Klotho Neurosciences, Inc. Granted FDA Orphan Drug Designation for KLTO-202 for Treatment of Amyotrophic Lateral Sclerosis ("ALS" or "Lou Gehrig's Disease")

PR Newswire 10 Jul 2025
NEW YORK, July 10, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (Nasdaq. KLTO), a gene and cell therapy company focused on the treatment of neurodegenerative and other aging-related diseases, today announced that the U.S ... Sinkule ... (NASDAQ ... 440k+ ... 9k+ ... .
Edit

ALS in Canada: Stats, impact and resources 

Canoe 09 Jul 2025
ALS, or amyotrophic lateral sclerosis, is devastating for people and their families to go through. The neurodegenerative disease affects nerve cells in the brain and spinal cord so that every muscle weakens and breaks down over time ... Advertisement 2 ... .
Edit

Amyotrophic Lateral Sclerosis Pipeline Appears Robust With 75+ Key Pharma Companies Actively Working in the ...

GetNews 08 Jul 2025
DelveInsight’s, “Amyotrophic Lateral Sclerosis Pipeline Insight, 2025,” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Amyotrophic Lateral Sclerosis (ALS) pipeline landscape.
Edit

Living with ALS: Navigating care and finding strength in community 'gives you hope'

Canoe 04 Jul 2025
Article content ... That was the beginning of the progressive pain that led to neurological tests for nerve function and a referral to Sunnybrook Hospital in Toronto to meet with a neurologist who specializes in ALS, or amyotrophic lateral sclerosis ... .
Edit

Former NHLer Mark Kirton living and leading with ALS: 'Be loud about it'

Canoe 27 Jun 2025
Story continues below ... Article content ... In 2018, he was diagnosed with ALS, or amyotrophic lateral sclerosis, a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord, gradually taking away mobility and function ... .

Article Search

tools
×
×
×
×